Let us bring COVID-19
testing to you
COVID-19 Testing & Services
COVID-19 Rapid Antigen Test
The COVID-Rapid Antigen test uses nasal swab specimens that will be collected by a Registered Nurse. This sample will be examined for the presence of protein fragments specific to the COVID-19 virus. This test offers prompt results, usually within 10-15 minutes.
$100
COVID-19 Nasal Swab Testing (PCR)
The COVID PCR (Polymerase Chain Reaction) is a diagnostic test utilizing nasal swab specimens that will be collected by a Registered Nurse. This sample detects viral RNA that is specific to the COVID-19 virus. Results typically arrive between 24-48 hours.
$175
Corporate COVID Testing Available
The Covid-19 Antigen Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. The antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of the disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.
COVID-19 Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meets the requirements to perform moderate, high or waived complexity tests. Negative results should be treated as presumptive, do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of an individual’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19 and confirmed with a molecular assay, if necessary, for patient management.